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ABSTRACT 
 
Background: The aim of this retrospective study was to identify subcategories in cT3-cT4a 
supraglottic/glottic cancers, describing their different spreading patterns, and local and 
loco-regional recurrence modes. 
Methods: Patients (N=489) who underwent open partial horizontal laryngectomies 
(OPHLs) were retrospectively classified as: subcategory I (anterior pT3 with normal 
arytenoid mobility), subcategory II (posterior pT3 with impaired/absent mobility), 
subcategory III (anterior pT4 with normal mobility), and subcategory IV (posterior pT4 with 
impaired/absent mobility). 
Results: Five-year overall, disease-specific, disease-free survivals, loco-regional, local 
control, freedom from laryngectomy, and laryngectomy-free survival were significantly 
better in anterior tumors (subcategories I and III) when compared to the corresponding 
posterior ones (subcategories II and IV). 
Conclusions: Anterior cT3 tumors are manageable by OPHL, and this approach could also 
be proposed in the treatment of early anterior cT4aN0. Despite promising results, OPHLs 
should be considered under investigation in posterior cT3 tumors due to clinical and 
biological behavior similar to cT4a tumors. 
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INTRODUCTION 
The current surgical treatment guidelines for laryngeal cancer in its intermediate/advanced 
categories distinguish T3 lesions in those amenable to partial versus total laryngectomy.1 
On the other hand, total laryngectomy remains the first therapeutic option for the T4a 
category, leaving non-surgical organ preservation protocols for selected patients refusing 
surgery. Nevertheless, to complicate matters further, a lack of evidence-based clear-cut 
consensus still exists on how to differentiate T3-T4a patients amenable to laryngeal 
conservation surgery from those requiring total laryngectomy. Different factors related to 
both the tumor and the patient2, 3 should indeed be considered when making an 
appropriate selection between patients treatable by the wide spectrum of open partial 
horizontal laryngectomies (OPHLs)4 and those requiring organ sacrifice. One possible 
source of confusion is related to the great heterogeneity of T3-T4a categories including a 
wide gamut of different lesions ranging f om T3 with minimal versus massive paraglottic 
space involvement (with normal or impaired/fixed vocal cord and arytenoid mobility), T3 
with preepiglottic space infiltration, T3 with thyroid cartilage erosion, T4 with purely anterior 
extralaryngeal extension, and T4 with posterior-inferior spreading through the lateral 
portion of the cricothyroid membrane and the crico-thyro-arytenoid space. The 
contemporary endoscopic5, 6 and imaging2, 7 work-ups have dramatically reduced the 
diagnostic uncertainty level in the pre-treatment setting. Notwithstanding this, no 
endoscopic technique or imaging refinement is as yet able to objectively quantify the 
degree and causes of reduced/absent motility of the vocal cord/crico-arytenoid unit.8 
Nowadays, several surgical and non-surgical options are available for treatment of T3-T4a 
laryngeal cancer, with comparable results in terms of loco-regional control, overall, and 
laryngectomy-free survival.9-11 Some large series published by different authors12-16 have 
shown that OPHLs4 allow sound and reproducible oncological outcomes to be obtained. 
Furthermore, these techniques are characterized by a high laryngectomy-free survival, 
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relatively low morbidity and mortality rates, and acceptable functional outcomes, if a 
careful preoperative patient selection is carried out. 
The aim of this multi-institutional retrospective study on T3-T4a laryngeal cancer patients 
treated by OPHLs was to identify, in the vast group of these lesions, some homogeneous 
subcategories describing their different patterns of spreading and related modes of local, 
and loco-regional recurrence. 
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PATIENTS AND METHODS 
Patients 
After comprehensive preoperative counseling, 479 patients (Table 1) underwent surgery 
between January 2000 and December 2012 at the Hospitals of Vittorio Veneto, Martini of 
Turin, and Policlinic Hospital of Modena. As previously described,15 patient selection was 
based on superficial and deep tumor extent, assessed by endoscopic and imaging 
evaluation performed less than 3 weeks before surgery. Computed tomography (CT) or 
magnetic resonance (MR) imaging was used to define infiltration of the cartilaginous 
framework, involvement of the pre-epiglottic (PES) and/or paraglottic spaces (PGS), as 
well as extralaryngeal spreading. Pre- and intraoperative videolaryngoscopic examination, 
by flexible endoscope in the office, and 0° and 70° rigid endoscopes in the operating 
theater, were employed to evaluate both vocal cord/arytenoid mobility and superficial 
tumor extent. Concerning arytenoid mobility, 293 patients showed impaired mobility/fixed 
vocal cord with mobile arytenoid, and 186 presented both vocal cord and arytenoid 
fixation. Patient characteristics, distribution according to the involved laryngeal sites, as 
well as their pT and pN categories, are reported in Table 1. 
The general eligibility criteria for OPHL were a histological diagnosis of 
intermediate/advanced (cT3-cT4a) categories of glottic and supraglottic laryngeal 
squamous cell carcinoma (SCC), and Karnofsky index17 higher than 80. Exclusion criteria 
were: purely supraglottic T3 with limited extension to the PES (and therefore amenable to 
OPHL type I or transoral laser microsurgery), previous treatment(s) for laryngeal 
carcinoma with curative intent, severe diabetes mellitus, severe bronchopulmonary chronic 
obstructive disease, neurological problems impairing the ability to expectorate and/or 
swallow, or severe cardiac disease. 
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pT subcategories 
Clinical, endoscopic, radiologic, surgical, and pathological reports were retrospectively 
assessed to divide patients into four subcategories based on a laryngeal 
compartmentalization using a vertical virtual plane tangential to the arytenoid vocal 
process and perpendicular to the ipsilateral thyroid lamina. We defined anterior and 
posterior laryngeal compartments as the portions located, respectively, anteriorly or 
posteriorly to such a plane (Fig. 1). The four subcategories identified are therefore as 
follows: 
I) Supraglottic/glottic/subglottic pT3, involving the anterior laryngeal compartment, with 
PES and anterior PGS involvement with/without inner cortex thyroid infiltration, but with 
normal arytenoid mobility (n=233 patients) (Fig. 2); 
II) Supraglottic/glottic/subglottic pT3, involving the posterior laryngeal compartment, with 
infiltration of the whole PGS with/without inner cortex thyroid invasion, and with impaired 
(reduced or absent) arytenoid mobility (n=157 patients) (Fig. 3); 
III) Supraglottic/glottic/subglottic pT4a, involving the anterior laryngeal compartment, with 
extralaryngeal extension (through the thyro-hyoid membrane, thyroid cartilage, and/or 
crico-thyroid membrane), but with normal arytenoid mobility (n=60 patients) (Fig. 4); 
IV) Supraglottic/glottic/subglottic pT4a, involving the posterior laryngeal compartment, with 
extralaryngeal extension (through or around the posterior portion of the thyroid lamina, 
through the lateral crico-thyroid membrane, cricoid cartilage, and/or at the level of the 
crico-thyroid-arytenoid space), and with impaired (reduced or absent) arytenoid mobility 
(n=29 patients) (Fig. 5). 
 
Surgical procedures 
All 479 patients underwent OPHL types II-III according to the European Laryngological 
Society Classification8 for curative purposes. Indications and contraindications of such 
Page 7 of 34
John Wiley & Sons, Inc.
Head & Neck
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
procedures have already been described in previous studies.12, 14, 15, 18, 19 The different 
types of surgical operation performed are reported in Table 2. 
Neck dissection (ND), graded according to the American Academy of Otolaryngology – 
Head and Neck Surgery Foundation Classification,20 was performed in 419 patients 
(87.5%), and was unilateral in 347 (82.8%) and bilateral in 72 (17.2%). ND was performed 
electively (ND levels II-IV) in 368 cN0 patients (87.8%) and for curative purposes in 51 
cN>0 (12.2%). In 391 patients (93.3%), level VI or unilateral paratracheal lymph node 
clearance was added. No ND was performed in 60 cN0 patients (12.5%). 
 
Adjuvant treatments 
Based on pathological findings, 62 patients (12.9%) were subjected to adjuvant 
radiotherapy. The indications were: pN+>1 (n=43 patients), gross extralaryngeal extension 
(n=17, of whom six showed positive ma gins), and positive margins elsewhere (n=2). A 
large volume encompassing the primary site and all draining lymph nodes were irradiated 
with a dose of up to 54 Gy. Regions at higher risk for malignant dissemination received a 
12 Gy boost (total, 66 Gy; range, 62–68 Gy). 
Furthermore, chemotherapy was added in 37 patients who received 100 mg/m2 of cisplatin 
on days 1, 22, and 43, concomitantly with radiotherapy because of a higher risk of local 
recurrence (five with Delphian nodes pN+, 20 pN2 with extracapsular spread, and 12 more 
extended pT4a showing positive/close margins toward pre-laryngeal tissues).21 
 
Statistical methods 
Clinical, endoscopic, and radiologic follow-up was performed for a mean of 5.3 years 
(range, 6 months–16.4 years). Overall (OS), disease-free (DFS), disease-specific (DSS) 
survivals, local (LC) and loco-regional (LRC) controls with OPHL alone, laryngectomy-free 
(LFS), and laryngo-esophageal dysfunction-free survivals (LEDFS)22 were assessed by 
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Kaplan–Meier curves. Log-rank (LR) and, for early events, Gehan-Breslow-Wilcoxon 
(GBW) tests were used to compare Kaplan–Meier estimates among the different 
subcategories. The end points considered were: the date of death (OS); the date of the 
first recurrence (DFS); the date of death from disease (DSS); the date of the first local 
recurrence (LC); the date of the first loco-regional recurrence (LRC); the date of salvage 
total laryngectomy or the date of death (LFS); the date of salvage total laryngectomy or the 
date of tracheostomy and/or PEG for functional reasons or the date of death (LEDFS). The 
association of prognostic factors for recurrence and subcategories was evaluated by odds 
ratio, meanwhile the corresponding incidences were compared by chi-squared (2) test. 
All analyses were performed with GraphPad Prism version 6.0e (GraphPad Software, San 
Diego, CA, USA), with p<0.05 as the threshold for statistical significance. 
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RESULTS 
Pathology 
Pathology reports showed close margins (<2 mm on the specimen side) in 59 cases 
(12.3%) and positive margins (negative at frozen sections but positive at the definitive 
histopathologic examination) in 16 (3.3%). 
Comparison between clinical and pathological staging showed up-staging of the primary 
tumor in 73 (15.2%) cT3 lesions that became pT4a (49 in subcategory III and 24 in 
subcategory IV), while 6 cT4a tumors became pT3 (3 in subcategory I and 3 in 
subcategory II). 
In total, 428 patients (89.3%) had been staged as cN0. In contrast, 40 (9.3%) of them 
became pN+ after ND. Overall, lymph node metastases were detected in 72 (15%) 
patients of whom 41 (8.6%) had multiple metastases (Table 1). 
 
Patterns of failure 
In total, 70 (14.6%) patients developed recurrences: 28 (40%) were local, 18 (25.7%) 
regional, and 4 (5.7%) loco-regional. Seven (10%) had local and distant recurrences, 2 
(2.8%) were regional and distant, whereas 10 (14.3%) developed distant metastasis only. 
One patient (1.4%) developed both loco-regional and distant recurrences. 
 
Survival and disease control according to different subcategories 
The 5-year estimates of the abovementioned oncologic outcomes for each subcategory 
are reported in Table 3. OS was significantly higher (p<0.01, with LR and GBW tests) in 
patients affected by anterior tumors (subcategories I and III, 92.7%) when compared with 
those treated for posterior ones (subcategories II and IV, 82.3%) (Fig. 6A). Moreover, 
anterior pT3 tumors (subcategory I) had better OS than posterior pT3 tumors (subcategory 
II, p<0.001, with LR and GBW tests), although no significant difference was detected 
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among pT4 tumors (subcategories III vs. IV). Finally, OS was hampered by T classification 
in anterior tumors (subcategories I vs. III, p<0.01, with LR and GBW tests), but not in 
posterior ones (subcategories II vs. IV). 
In the same way, DSS was affected by the described laryngeal compartmentalization: it 
was 96.3% in anterior (subcategories I and III) and 90.1% in posterior tumors 
(subcategories II and IV) (p<0.05, with LR and GBW tests) (Fig. 6B). A statistically 
significant difference was also demonstrated when comparing anterior (subcategory I) and 
posterior (subcategory II) pT3 tumors (p<0.05, with LR and GBW tests), but not when 
analyzing pT4 tumors (subcategories III vs. IV), even though they had a similar trend. 
Finally, no difference in terms of DSS was detected by comparison of pT3 and pT4 tumors 
located in the same laryngeal compartment (subcategories I vs. III and II vs. IV). 
DFS was significantly reduced in posterior (subcategories II and IV, 78.8%) compared to 
anterior tumors (subcategories I and III, 88.3%) (p<0.05, with LR and GBW tests) (Fig. 
6C). Likewise, posterior pT3 (subcategory II) had worse DFS (p<0.05, with LR and GBW 
tests) than anterior pT3 tumors (subcategory I), although no significant difference was 
detected among subcategories III and IV. Moreover, patients treated for pT4 tumors had 
more recurrences than those with pT3 neoplasms independently from the antero-posterior 
localization of the disease (subcategories I vs. III, p<0.01; subcategories II vs. IV, p<0.05, 
with LR and GBW tests). 
LRC was not significantly different between anterior (subcategories I and III, 88.6%) and 
posterior tumors (subcategories II and IV, 83.3%) (Fig. 6D). Nevertheless, it was better in 
subcategory I than in subcategory II (p<0.05, with LR test), although pT4 (subcategories III 
and IV) had comparable results. Finally, T status affected LRC of anterior tumors 
(subcategories I vs. III, p<0.01, with LR and GBW tests), but not that of posterior ones 
(subcategories II vs. IV). 
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Likewise, LC was similar in anterior (subcategories I and III, 92.7%) and posterior tumors 
(subcategories II and IV, 88.1%) (Fig. 6E). Again, subcategory I had better control than 
subcategory II (p<0.05, with LR test), whereas no significant difference was detected when 
comparing pT4 (subcategories III vs. IV). 
Patients affected by anterior tumors were less prone to fatal outcomes and had less need 
of salvage total laryngectomy than those with posterior ones (LFS 90.1% for subcategories 
I and III and 75.7% for subcategories II and IV; p<0.001 with LR test and p<0.01 with GBW 
test) (Fig. 6F). Subcategory I had better LFS than subcategory II (p<0.001, with LR and 
GBW tests), but no significant difference was detected between subcategories III and IV. 
Finally, LFS was higher in anterior pT3 than in anterior pT4 tumors (p<0.01, with LR and 
GBW tests), whereas posterior pT3 had better LFS with respect to posterior pT4 tumors as 
an early event only (p<0.05, with GBW test). 
Similarly, the LEDFS was higher in anterior (subcategories I and III, 88.8%) than in 
posterior tumors (subcategories II and IV, 74.9%, p<0.001, with LR test and p<0.01, with 
GBW test) (Fig. 6G). Again, despite no significant difference being detected between pT4 
tumors (subcategories III vs. IV), anterior pT3 (subcategory I) had better LEDFS than 
posterior pT3 tumors (subcategory II, p<0.001, with LR and GBW tests). Furthermore, only 
anterior tumors were affected by T classification: anterior pT4 (subcategory III) had worse 
LEDFS (p<0.001, with LR and GBW tests) than anterior pT3 (subcategory I). 
 
Correlation between each subcategory and factors affecting loco-regional recurrence 
The associations between positive or close margins, pN+, level VI pN+, extracapsular 
spread (ECS) and subcategories have been evaluated and results are summarized in 
Table 4. 
Tumor localization was generally associated with the occurrence of ECS alone: its risk of 
occurrence was indeed higher in posterior (subcategories II and IV) than in anterior tumors 
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(subcategories I and III) (p<0.05). Despite being not significantly different, the occurrence 
of ECS appeared to be more frequent in subcategory IV. 
The prevalence of positive margins was homogeneous amongst the subcategories, but 
their occurrence was significantly more frequent in pT4a when compared with pT3 tumors 
(subcategory III vs. I, p<0.05; subcategory IV vs. II, p<0.001). Similarly, no statistically 
significant difference was detected in terms of pN+ prevalence amongst the subcategories, 
but lymph node involvement at level VI was more common in patients affected by pT4a 
tumors, with respect to those with pT3 tumors (subcategory III vs. I, p<0.001; subcategory 
IV vs. II, p<0.01). 
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DISCUSSION 
The last two decades have gradually witnessed a paradigm shift in the treatment of 
laryngeal cancer, with a progressively increasing significance given to organ and function 
preservation.9-11, 15, 16 Focusing on advanced stages, all the therapeutic approaches, non-
surgical as well as surgical by OPHLs, have demonstrated that larynx preservation is 
feasible, even though some disappointing long-term results of chemoradiotherapy (CRT) 
protocols deserve further evaluation and investigation.9, 23 
Despite the undoubted advantages deriving from the laryngeal function preservation 
approach in terms of quality of life, laryngeal oncology has struggled to develop like other 
subspecialties in oncology, probably because of the major push towards organ 
preservation by non-surgical modalities. In fact, this paper clearly demonstrates that 
excellent results can be obtained even though the application of surgical function sparing 
strategies like OPHLs maintained that particular accuracy in their indications and limits are 
observed. From this perspective, the implementation of correct OPHL indications, rather 
than the surgical technique itself, is probably one of the most important keys to success in 
this type of surgery. 
Assuming that total laryngectomy is the safest treatment for laryngeal cancer in 
intermediate and advanced stages, any therapeutic approach attempting to preserve the 
larynx should be based on careful case selection, where a pivotal role is taken by patient- 
and tumor-related parameters. For this reason, meaningful direct comparisons between 
the oncologic and functional outcomes of CRT, total laryngectomy and OPHLs are lacking 
in the current literature for the very reason that they are quite difficult, if not impossible, to 
be comprehensively made. For the innate diversity (in terms of staging, comorbidity, 
willingness, age, gender, profession, previous treatments, etc.) of those patients 
considered amenable to one treatment versus another, a true comparison of crude data 
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like survival or swallowing/voice (just to mention the most obvious) is far beyond the real 
possibilities of any prospective or retrospective analysis. 
OPHL can be offered to patients as a valuable alternative to preserve part of the larynx 
and its functions, even in advanced T categories, avoiding the negative physical and 
psychosocial impacts of a permanent tracheostomy15, 16, 19. After a strict selection of 
patients (based on the assessment of good general and functional conditions, the absence 
of clinically positive neck nodes and a good compliance to an intensive rehabilitation 
protocol), different types of partial laryngectomy can be proposed. When a patient accepts 
a conservative surgical management approach, in fact, an OPHL type I, IIa, IIb, IIIa or IIIb 
may be performed guided by intraoperative evaluations confirmed by frozen sections. This 
kind of flexibility and customized surgical approach requires specific expertise and, 
therefore, centralization of such cases in sufficiently large reference centers.  
Further aspects to be considered during pre-treatment multidisciplinary visit are the well-
known absolute contraindications to OPHL type II and III, which are based on T and N 
stage. 
In our experience, these are represented by: i) lesions extended to base of tongue or 
pyriform sinus; ii) lesions with major invasion of pre-epiglottic space involving the hyoid 
bone, lesion involving the inter-arytenoid space, the posterior commissure and both 
arytenoid cartilages; iii) large extralaryngeal spread of cancer involving thyroid gland, strap 
muscles, cervical skin, internal jugular vein or common carotid artery; and iv) lesions 
reaching the first tracheal ring.  
The suspected presence of clinically positive nodes >cN1 is not an absolute 
contraindication. However, it does not represent a good indication to OPHL due to the 
probable need for a post-operative RT: the first goal of a function sparing surgical 
approach should indeed be to get a single-shot therapy. 
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In the present series, stringent clinical-radiological selection criteria have been adopted to 
identify homogeneous cT3 and cT4 subcategories that may be treated by OPHL type II – 
III with the best chance of success. For both supraglottic and glottic T3 and T4 tumors, the 
most crucial prognosticator appears to be involvement of the posterior PGS, usually 
associated with reduced mobility or fixation of the ipsilateral arytenoid. This simple criterion 
of anterior vs. posterior laryngeal compartmentalization has herein been demonstrated to 
be a useful adjunctive parameter to be included in preoperative therapeutic planning. 
In fact, when dealing with anterior T3 tumors with normal vocal cord/arytenoid mobility 
(subcategory I), OPHL compares favorably with transoral laser microsurgery (TLM) (whose 
local control has been shown to be in the range of 44–72% for glottic and 70–87% for 
supraglottic tumors),24-27 and with CRT (whose 2-year laryngo-esophageal dysfunction-
free survival has been reported to be around 40%).28 The inner thyroid lamina infiltration 
does not negatively impact on the possibility to attain adequate disease control by such an 
open-neck conservative approach, while this is definitely the case for TLM and the issue is 
still debated for CRT. 
Considering anterior T4 tumors (subcategory III), OPHL allows quite favorable oncologic 
outcomes that can only be compared with those described after total laryngectomy. Here 
the difference is in terms of a better quality of life and function preservation of the larynx. 
Interestingly, our series highlights that there is not a great difference in terms of OS, DSS, 
and LFS between subcategory I and III when these lesions have been addressed by 
OPHL. 
In contrast, the posterior lesions are much more troublesome and definitely represent the 
most difficult clinical scenario. Posterior T3 tumors with vocal cord/arytenoid fixation 
(subcategory II) have been shown to offer very poor outcomes when treated by either TLM 
or CRT. Even using OPHLs, the oncologic outcomes are significantly worse in this 
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subcategory when compared to anterior tumors (OS p<0.001, DSS p<0.05, and DFS 
p<0.001).  
OPHLs for T3 cancer affecting arytenoid motility requires a detailed knowledge of tumor 
growth and diffusion patterns. Traditionally, arytenoid fixation was adopted as an exclusion 
criterion for OPHLs. However, in a study on 77 cases, Katilmis et al. focused on the 
possible different causes of arytenoid fixation: involvement of intrinsic laryngeal muscles 
with insertion on the arytenoid, crico-arytenoid joint invasion, and recurrent nerve 
infiltration.29 Beyond these, another cause of reduced/absent arytenoid mobility is 
represented by the tumor mass effect, which is present in about 60% of supraglottic 
lesions. Therefore, an adequate preoperative endoscopic and imaging work-up able to 
reliably distinguish among such different causes of arytenoid fixation is strongly warranted 
and might in future greatly help in subclassifying these lesions according to more detailed 
etiologies. This may also mean that posterior T3 tumors could be considered more similar 
to T4 from an oncologic as well as from a functional point of view. Even from an anatomic 
perspective, posterior T3 tumors can present cricoarytenoid joint invasion, cricoid plate 
infiltration, as well as lateral cricoarytenoid muscle involvement, or perineural spreading 
along the recurrent nerve. These factors allow tumors to grow outside the laryngeal box, 
towards the hypopharynx and cervical soft tissues. Once the tumor has gained the thyro-
cricoarytenoid gateway, it is indeed almost outside the larynx and, in this sense, it is 
prognostically more similar to T4 cancer. Moreover, in posterior T3-T4 tumors, the risk of 
occurrence of lymph nodes with ECS is 2.5 times higher than in anterior lesions, and the 
occurrence of close margins is 2.4 times higher in anterior pT4 than in pT3, and 8.1 times 
higher in posterior lesions. In light of this, OPHL should be reserved for very carefully 
selected cases of posterior T3 (and even less frequently in posterior T4 or subcategory IV) 
since, even from a functional point of view, OPHL type III + CAU (removal of one 
cricoarytenoid unit) definitively represents an “extreme” conservative surgery with several 
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technical difficulties and sometimes unpredictable outcomes. Therefore, in posterior T3-T4 
tumors, total laryngectomy (with adjuvant CRT or RT) should remain the mainstay of 
treatment. 
Another advantage of OPHLs type II – III is their respectable functional outcomes whose 
occurrences have been summarized in Table 5. As a matter of fact, use of OPHL allows 
quite good results to be obtained in terms of the composite end point represented by 
LEDFS. Even from this point of view, anterior pT3 (subcategory I) had better LEDFS than 
posterior pT3 tumors (subcategory II, p<0.001, with LR and GBW tests). 
Recently, comparing CRT versus primary surgery, Timme et al.  showed that some 
selected patients with locally advanced laryngeal cancer can be offered non-surgical organ 
preservation without compromising survival.28 However, these have higher rates of 
laryngeal and esophageal dysfunction than those obtained by OPHLs.  
 
CONCLUSIONS 
OPHLs type II – III for intermediate/locally advanced laryngeal cancer provide good 
oncological and functional outcomes only if strict patient and tumor selection criteria are 
followed. Concerning the cT3 category, anterior tumors sparing the posterior PGS and not 
affecting arytenoid mobility are definitely manageable by such a surgical approach with 
excellent oncologic outcomes. OPHLs could also be offered to patients affected by early 
anterior cT4aN0, strongly motivated to avoid total laryngectomy and declining concurrent 
CRT. 
Even though associated with more than promising results, probably due to the strict criteria 
used to select the subset of patients more suitable for partial laryngectomies, this 
conservative surgical approach should be carefully applied in cases of cT3 tumors 
reaching the posterior PGS and causing arytenoid fixation. In fact, the subset of patients 
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belonging to subcategory II comprises tumors characterized by biological behavior as well 
as oncologic results that appear very similar to those of T4a cancers. 
Anyway, a new method of selecting cases amenable to OPHL should first keep in mind the 
absolute local and general contraindications to this type of surgery. 
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FIGURE LEGENDS 
 
Fig. 1 – Anatomical drawings representing the anterior and posterior laryngeal 
compartments defined by a vertical plane tangential to the arytenoid vocal process and 
perpendicular to the ipsilateral thyroid lamina: A) axial; B) sagittal views. 
 
Fig. 2 – Anatomical drawings representing the possible tumor presentations in 
subcategory I. A) Supraglottic cT3 extending to the PES and anterior commissure; B) 
supraglottic cT3 with PES and anterior PGS involvement; C) glotto-supraglottic cT3 with 
anterior PGS and infrapetiole region involvement; D) glottic cT3 with anterior PGS 
involvement; E) glottic cT3 with anterior PGS, internal thyroid lamina, and anterior 
commissure involvement; F) glottic-subglottic cT3 with anterior PGS and subglottic 
mucosa involvement. 
 
Fig. 3 – Anatomical drawings representing the possible tumor presentations in 
subcategory II. A) Supraglottic cT3 with superior and posterior PGS and arytenoid 
involvement; B) glottic cT3 with whole PGS involvement; C) glottic cT3 with whole PGS 
and internal thyroid lamina involvement; D) glotto-subglottic cT3 with posterior PGS and 
crico-arytenoid joint involvement. 
 
Fig. 4 – Anatomical drawings representing the possible tumor presentations in 
subcategory III. A) Anterior supraglottic cT4a with extension through the thyro-hyoid 
membrane and thyroid cartilage; B) anterior glottic cT4a with extension through the thyroid 
cartilage and crico-thyroid membrane. 
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Fig. 5 – Anatomical drawings representing the possible tumor presentations in 
subcategory IV. A) Posterior glottic cT4a with extension through the crico-thyroid 
membrane; B) posterior transglottic cT4a with extension through the thyroid cartilage and 
cricoid involvement. 
 
Fig. 6 – A) Overall survival, B) disease-specific survival, C) disease-free survival, D) 
locoregional control, E) local control, F) laryngectomy-free survival, and G) laryngo-
esophageal dysfunction-free survival for the entire cohort. Log-Rank test: *p<0.05; 
**p<0.01; ***p<0.001. Gehan-Breslow-Wilcoxon test: #p<0.05; ##p<0.01. 
 
 
Page 23 of 34
John Wiley & Sons, Inc.
Head & Neck
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Table 1 – Epidemiologic and clinical characteristics of patients treated by OPHL in the present series (N=479). 
  
No of 
patients 
(%) 
Age 
Mean ± standard 
deviation 
60.0±9.2 
 Range 16-83 
Gender Male 434 (90.6%) 
 Female 45 (  9.4%) 
Karnofsky 100 298 (62.2%) 
 90 181 (37.8%) 
Arytenoid 
mobility 
Normal 293 (61.2%) 
 Impaired/fixed 186 (38.8%) 
   
pTN Glottic Supraglottic 
pT3 N0 290 (60.5%) 46 (  9.6%) 
 N1 15 (  3.1%) 8 (  1.7%) 
 N2 18 (  3.8%) 13 (  2.7%) 
pT4a N0 69 (14.4%) 2 (  0.4%) 
 N1 8 (  1.7%) 0 (  0.0%) 
 N2 7 (  1.5%) 3 (  0.6%) 
Total  407 (85.0%) 72 (15.0%) 
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Table 2 – Surgical procedures performed in the 479 patients included in this study 
OPHL type Subcategory I  Subcategory II  Subcategory III Subcategory IV  
IIa, n (%) 33/233 (14.2%) 15/157 (  9.6%) 7/60 (11.7%) 4/29 (13.8%) 
IIa + ARY, n (%) 125/233 (53.6%) 69/157 (43.9%) 11/60 (18.3%) 6/29 (20.7%) 
IIb, n (%) 19/233 (  8.2%) 6/157 (  3.8%) 6/60 (10.0%) 0/29 (  0.0%) 
IIb + ARY, n (%) 49/233 (21.0%) 37/157 (23.6%) 19/60 (31.7%) 5/29 (17.3%) 
IIIa, n (%) 1/233 (  0.4%) 2/157 (  1.3%) 3/60 (  5.0%) 1/29 (  3.4%) 
IIIa + CAU, n (%) 6/233 (  2.6%) 28/157 (17.8%) 10/60 (16.7%) 10/29 (34.5%) 
IIIb, n (%) 0/233 (  0.0%) 0/157 (  0.0%) 2/60 (  3.3%) 1/29 (  3.4%) 
IIIb + CAU, n (%) 0/233 (  0.0%) 0/157 (  0.0%) 2/60 (  3.3%) 2/29 (  6.9%) 
IIa: supracricoid partial laryngectomy with crico-hyoido-epiglottopexy; IIb: supracricoid partial 
laryngectomy with crico-hyoidopexy; IIIa: supratracheal partial laryngectomy with tracheo-hyoido-
epiglottopexy; IIIb: supratracheal partial laryngectomy with tracheo-hyoidopexy; ARY: removal of 
one arytenoid; CAU: removal of one cricoarytenoid unit. 
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Table 3 – Kaplam-Meier estimates of 5-year oncologicoutcomes stratified according to 
subcategory 
 
 Subcategory 
 I II III IV 
OS, % 95.0 82.8 82.9 79.9 
DSS, % 97.0 90.7 93.6 86.5 
DFS, % 91.5 81.2 74.6 64.2 
LRC, % 91.9 84.2 74.6 77.3 
LC, % 96.0 89.1 78.1 81.6 
LFS, % 93.0 77.7 77.2 64.1 
LEDFS, % 93.1 76.6 70.4 64.7 
OS = overall survival; DSS = disease-specific survival; DFS = disease-free survival; LRC = locoregional 
control; LC = local control; LFS = laryngectomy-free survival; LEDFS = laryngo-esophageal 
dysfunction-free survival. 
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Table 4 –  Prognostic factors for recurrences. ODDS Ratio and 2 analyses amongst subcategories. 
 
 Subcategory 
 II vs. I IV vs. III III vs. I IV vs. II II+IV vs. I+III  
ODDS Ratio       
Close margins 0.65 2.20 2.41 8.13 0.93  
Positive margins 2.70 1.40 3.12 1.61 2.08  
pN+ 1.69 2.13 1.74 2.20 1.32  
Level VI+ 3.77 2.32 11.69 7.20 2.14  
ECS 2.03 7.51 1.09 4.05 2.53  
       
χ2       
Close margins 0.349 0.172 0.032 0.000 0.907  
Positive margins 0.196 0.899 0.312 0.927 0.233  
pN+ 0.514 0.470 0.330 0.179 0.353  
Level VI+ 0.106 0.418 0.000 0.006 0.118  
ECS 0.292 0.062 0.766 0.076 0.047  
ECS, extracapsular spread. 
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Table 5 – Occurrence of functional impairments after OPHLs stratified according to subcategory 
 
 Subcategory 
 I II III IV 
Permanent nasogastric tube 1/233 (0.4%) 0/157 (0.0%) 0/60 (0.0%) 3/29 (10.3%) 
Permanent percutaneous 
endoscopic gastrostomy 
4/233 (1.7%) 0/157 (0.0%) 0/60 (0.0%) 1/29 (  3.4%) 
Permanent tracheostomy 3/233 (1.3%) 8/157 (5.1%) 4/60 (6.7%) 2/29 (  6.9%) 
Severe vocal communication 
impairment 
2/233 (0.8%) 6/157 (3.8%) 2/60 (3.3%) 1/29 (  3.4%) 
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Anatomical drawings representing the anterior and posterior laryngeal compartments defined by a vertical 
plane tangential to the arytenoid vocal process and perpendicular to the ipsilateral thyroid lamina: A) axial; 
B) sagittal views.  
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Anatomical drawings representing the possible tumor presentations in subcategory I. A) Supraglottic cT3 
extending to the PES and anterior commissure; B) supraglottic cT3 with PES and anterior PGS involvement; 
C) glotto-supraglottic cT3 with anterior PGS and infrapetiole region involvement; D) glottic cT3 with anterior 
PGS involvement; E) glottic cT3 with anterior PGS, internal thyroid lamina, and anterior commissure 
involvement; F) glottic-subglottic cT3 with anterior PGS and subglottic mucosa involvement.  
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Anatomical drawings representing the possible tumor presentations in subcategory II. A) Supraglottic cT3 
with superior and posterior PGS and arytenoid involvement; B) glottic cT3 with whole PGS involvement; C) 
glottic cT3 with whole PGS and internal thyroid lamina involvement; D) glotto-subglottic cT3 with posterior 
PGS and crico-arytenoid joint involvement.  
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Anatomical drawings representing the possible tumor presentations in subcategory III. A) Anterior 
supraglottic cT4a with extension through the thyro-hyoid membrane and thyroid cartilage; B) anterior glottic 
cT4a with extension through the thyroid cartilage and crico-thyroid membrane.  
 
140x78mm (300 x 300 DPI)  
 
 
Page 32 of 34
John Wiley & Sons, Inc.
Head & Neck
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Anatomical drawings representing the possible tumor presentations in subcategory IV. A) Posterior glottic 
cT4a with extension through the crico-thyroid membrane; B) posterior transglottic cT4a with extension 
through the thyroid cartilage and cricoid involvement.  
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A) Overall survival, B) disease-specific survival, C) disease-free survival, D) locoregional control, E) local 
control, F) laryngectomy-free survival, and G) laryngo-esophageal dysfunction-free survival for the entire 
cohort. Log-Rank test: *p<0.05; **p<0.01; ***p<0.001. Gehan-Breslow-Wilcoxon test: #p<0.05; 
##p<0.01.  
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